This case highlights the risk of recurrent acute profound thrombocytopenia upon readministration of eptifibatide in patients undergoing PCI.
Suggests caution with eptifibatide readministration after prior thrombocytopenia; leaves open incidence and risk factors in PCI patients.
We describe the case of an 86-year-old woman who presented with unstable angina. She was given heparin and eptifibatide, and she underwent percutaneous coronary intervention (PCI). Shortly thereafter, she developed acute profound thrombocytopenia (6,000 platelets/mm3), which resolved after the discontinuation of heparin and eptifibatide. Four months later, she presented again with unstable angina and underwent PCI. Soon after the procedure, she again developed acute profound thrombocytopenia (2,000 platelets/mm3). To our knowledge, acute profound thrombocytopenia due to eptifibatide treatment in the same patient at two different times has not been reported before.
No takes yet. Share an insight, caveat, or question.
Cheema et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: